Nitrofurantoin Dosing for Uncomplicated UTI
The recommended dosage of nitrofurantoin monohydrate/macrocrystals (Macrobid) for treating uncomplicated urinary tract infections is 100 mg twice daily for 5 days. 1, 2, 3
First-Line Treatment Recommendation
- Nitrofurantoin is recommended as a first-line agent for uncomplicated UTIs by both the Infectious Diseases Society of America (IDSA) and the European Association of Urology due to its high efficacy and low resistance rates 1, 3
- Clinical cure rates with nitrofurantoin range from 88-93% for uncomplicated UTIs in women 1
- Bacterial cure rates range from 81-92% for uncomplicated UTIs in women 1
Dosing Specifics
- The standard formulation used is nitrofurantoin monohydrate/macrocrystals (Macrobid) at 100 mg twice daily 1, 2
- The recommended duration is 5 days for uncomplicated UTIs in women 1, 2
- Alternative formulation: nitrofurantoin macrocrystals can be used at a dose of 50-100 mg four times daily for 5 days 1
Important Contraindications
- Nitrofurantoin is contraindicated in patients with creatinine clearance <60 mL/min due to:
- Nitrofurantoin should be avoided if early pyelonephritis is suspected 1
Alternative First-Line Options
When nitrofurantoin cannot be used, consider:
- Fosfomycin trometamol 3 g single dose (slightly lower efficacy than nitrofurantoin) 1
- Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days (only if local resistance rates <20% or if the infecting strain is confirmed susceptible) 1, 2
- For patients with renal impairment (CrCl <60 mL/min), consider trimethoprim-sulfamethoxazole or fosfomycin trometamol as alternatives 2
Efficacy Comparison
- The 5-day regimen of nitrofurantoin (100 mg twice daily) has been shown to be equivalent to trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days) in clinical and microbiological cure rates 1, 4
- Nitrofurantoin has similar clinical cure rates to ciprofloxacin and trimethoprim-sulfamethoxazole when comparing 7-day regimens 1
Common Side Effects and Monitoring
- Most common side effects include nausea and headache 1
- Adverse event rates range from 5.6-34% across studies 1
- Headache occurs in approximately 10.8% of patients 5
- Monitor for signs of toxicity in patients with borderline renal function, including peripheral neuropathy, pulmonary reactions, and hepatotoxicity 2
Follow-up Recommendations
- Routine post-treatment urinalysis or urine cultures are not indicated for asymptomatic patients 1
- For women whose symptoms do not resolve by the end of treatment or recur within 2 weeks, obtain a urine culture with susceptibility testing 1
- Consider retreatment with a 7-day regimen using another agent if symptoms persist or recur 1